Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, Lim J, Soong J, Link E, Blombery P, Thompson ER, Fellowes A, Sheppard KE, McArthur GA, Pearson RB, Hannan RD, Poortinga G, Harrison SJ.

Cancer Discov. 2019 Aug;9(8):1036-1049. doi: 10.1158/2159-8290.CD-18-1455. Epub 2019 May 15.

PMID:
31092402
2.

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G.

Commun Biol. 2019 Jan 28;2:39. doi: 10.1038/s42003-019-0284-y. eCollection 2019.

3.

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.

Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220. Epub 2018 Jan 3.

4.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD.

Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10.

5.

Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.

Kerry LE, Pegg EE, Cameron DP, Budzak J, Poortinga G, Hannan KM, Hannan RD, Rudenko G.

PLoS Negl Trop Dis. 2017 Mar 6;11(3):e0005432. doi: 10.1371/journal.pntd.0005432. eCollection 2017 Mar.

6.

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.

Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L, Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L.

Clin Cancer Res. 2016 Nov 15;22(22):5539-5552. doi: 10.1158/1078-0432.CCR-16-0124. Epub 2016 Aug 2.

7.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

8.

A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes.

Sanij E, Diesch J, Lesmana A, Poortinga G, Hein N, Lidgerwood G, Cameron DP, Ellul J, Goodall GJ, Wong LH, Dhillon AS, Hamdane N, Rothblum LI, Pearson RB, Haviv I, Moss T, Hannan RD.

Genome Res. 2015 Feb;25(2):201-12. doi: 10.1101/gr.176115.114. Epub 2014 Dec 1.

9.

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, Fox SB, Dutton-Regester K, Hayward NK, Jene N, Dobrovic A, Pearson RB, Christensen JG, Randolph S, McArthur GA, Sheppard KE.

Pigment Cell Melanoma Res. 2014 Jul;27(4):590-600. doi: 10.1111/pcmr.12228. Epub 2014 Mar 6.

PMID:
24495407
10.

A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing.

Cardinal JW, Bergman L, Hayward N, Sweet A, Warner J, Marks L, Learoyd D, Dwight T, Robinson B, Epstein M, Smith M, Teh BT, Cameron DP, Prins JB.

J Med Genet. 2005 Jan;42(1):69-74.

11.

Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation.

Hutley LJ, Newell FM, Joyner JM, Suchting SJ, Herington AC, Cameron DP, Prins JB.

Eur J Clin Invest. 2003 Jul;33(7):574-81.

PMID:
12814394
12.

Estrogen receptors in human preadipocytes.

Joyner JM, Hutley LJ, Cameron DP.

Endocrine. 2001 Jul;15(2):225-30.

PMID:
11720251
13.

Human adipose tissue endothelial cells promote preadipocyte proliferation.

Hutley LJ, Herington AC, Shurety W, Cheung C, Vesey DA, Cameron DP, Prins JB.

Am J Physiol Endocrinol Metab. 2001 Nov;281(5):E1037-44.

14.

Increased susceptibility to streptozotocin-induced beta-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N-glycosylase-deficient mice.

Cardinal JW, Margison GP, Mynett KJ, Yates AP, Cameron DP, Elder RH.

Mol Cell Biol. 2001 Aug;21(16):5605-13.

15.

Familial Paget's disease of bone: nonlinkage to the PDB1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree.

Good D, Busfield F, Duffy D, Lovelock PK, Kesting JB, Cameron DP, Shaw JT.

J Bone Miner Res. 2001 Jan;16(1):33-8.

16.

Glucocorticoid receptors in human preadipocytes: regional and gender differences.

Joyner JM, Hutley LJ, Cameron DP.

J Endocrinol. 2000 Jul;166(1):145-52.

PMID:
10856893
17.
18.

"Eyes-open optimism": one view of the future for physicians.

Cameron DP.

Med J Aust. 2000 Jan 3;172(1):36-7. No abstract available.

PMID:
10682017
19.

Apolipoprotein E polymorphism in indigenous Australians: allelic frequencies and relationship with dyslipidaemia.

Shaw JT, Tate J, Kesting JB, Marczak M, Berkholz JR, Lovelock PK, Purdie D, Hickman P, Cameron DP.

Med J Aust. 1999 Feb 15;170(4):161-4.

PMID:
10078180
20.

Plasma homocysteine levels in indigenous Australians.

Shaw JT, McWhinney B, Tate JR, Kesting JB, Marczak M, Purdie D, Gibbs H, Cameron DP, Hickman PE.

Med J Aust. 1999 Jan 4;170(1):19-22.

PMID:
10026668
21.
22.

Novel susceptibility gene for late-onset NIDDM is localized to human chromosome 12q.

Shaw JT, Lovelock PK, Kesting JB, Cardinal J, Duffy D, Wainwright B, Cameron DP.

Diabetes. 1998 Nov;47(11):1793-6.

PMID:
9792550
23.
24.

Tumor necrosis factor-alpha induces apoptosis of human adipose cells.

Prins JB, Niesler CU, Winterford CM, Bright NA, Siddle K, O'Rahilly S, Walker NI, Cameron DP.

Diabetes. 1997 Dec;46(12):1939-44.

PMID:
9392477
25.

Metyrapone pre-treated inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome.

Cuneo RC, Lee W, Harper J, Mitchell K, Ward G, Atkinson RL, Salkield I, Cameron DP.

Clin Endocrinol (Oxf). 1997 May;46(5):607-18. Erratum in: Clin Endocrinol (Oxf) 1997 Sep;47(3):378.

PMID:
9231057
26.

Apoptosis is the mode of beta-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse.

O'Brien BA, Harmon BV, Cameron DP, Allan DJ.

Diabetes. 1997 May;46(5):750-7.

PMID:
9133540
27.

Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic beta cell line, INS-1.

Saini KS, Thompson C, Winterford CM, Walker NI, Cameron DP.

Biochem Mol Biol Int. 1996 Aug;39(6):1229-36.

PMID:
8876977
28.

Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model.

O'Brien BA, Harmon BV, Cameron DP, Allan DJ.

J Pathol. 1996 Feb;178(2):176-81.

PMID:
8683386
29.

G protein mutations in tumours of the pituitary, parathyroid and endocrine pancreas.

Boothroyd CV, Grimmond SM, Cameron DP, Hayward NK.

Biochem Biophys Res Commun. 1995 Jun 26;211(3):1063-70.

PMID:
7598693
30.

Human adipocyte apoptosis occurs in malignancy.

Prins JB, Walker NI, Winterford CM, Cameron DP.

Biochem Biophys Res Commun. 1994 Nov 30;205(1):625-30.

PMID:
7999091
31.

Apoptosis of human adipocytes in vitro.

Prins JB, Walker NI, Winterford CM, Cameron DP.

Biochem Biophys Res Commun. 1994 Jun 15;201(2):500-7.

PMID:
8002979
32.

Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se.

McIntyre HD, Ma A, Bird DM, Patterson CA, Cameron DP.

Diabetes Care. 1992 Nov;15(11):1534-40.

PMID:
1468283
33.

Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol.

Morgan TO, Louis WJ, MacDonald GJ, Conway EL, Bartholomeusz LC, Anderson AI, Cameron DP, Donnelly T, Frewin DB, Hooper MJ, et al.

Am J Med. 1992 Apr 27;92(4B):73S-78S.

PMID:
1580284
34.

Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus.

McIntyre HD, Ma A, Bird DM, Paterson CA, Ravenscroft PJ, Cameron DP.

Aust N Z J Med. 1991 Oct;21(5):714-9.

PMID:
1759920
35.
36.

Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.

McIntyre HD, Cameron DP, Urquhart SM, Davies WE.

Postgrad Med J. 1989 Apr;65(762):244-6.

37.

The effects of long term gliclazide administration on insulin secretion and insulin sensitivity.

Ma A, Kamp M, Bird D, Howlett V, Cameron DP.

Aust N Z J Med. 1989 Feb;19(1):44-9.

PMID:
2669710
38.
39.

Phaeochromocytoma and cardiomyopathy.

Scott I, Parkes R, Cameron DP.

Med J Aust. 1988 Jan 18;148(2):94-6.

PMID:
3336345
40.

Regulation of feeding behaviour in monosodium glutamate (MSG) treated mice.

Ma V, Ma A, Cameron DP.

Life Sci. 1988;42(15):1419-24.

PMID:
2832677
41.

Post-prandial glucose and insulin responses to different types of spaghetti and bread.

d'Emden MC, Marwick TH, Dreghorn J, Howlett VL, Cameron DP.

Diabetes Res Clin Pract. 1987 Jul-Aug;3(4):221-6.

PMID:
3304910
42.

Cafeteria feeding promotes diet-induced thermogenesis in monosodium glutamate-treated mice.

Moss D, Ma A, Cameron DP.

Metabolism. 1985 Dec;34(12):1094-9.

PMID:
4069008
43.

Defective thermoregulatory thermogenesis in monosodium glutamate-induced obesity in mice.

Moss D, Ma A, Cameron DP.

Metabolism. 1985 Jul;34(7):626-30.

PMID:
4010523
44.

Toxic adenoma in childhood--case report.

Lepre F, Cameron DP, Hartley L.

Aust Paediatr J. 1983 Dec;19(4):258-9.

PMID:
6673728
45.

Glycosylated plasma protein: a simple method for the elimination of interference by glucose in its estimation.

Ma A, Naughton MA, Cameron DP.

Clin Chim Acta. 1981 Sep 10;115(2):111-7.

PMID:
7285359
46.

Secondary amenorrhoea due to autoimmune ovarian failure.

Leer J, Patel B, Innes M, Cameron DP.

Aust N Z J Obstet Gynaecol. 1980 Aug;20(3):177-9.

PMID:
6257223
47.

Endocrine influences on serum acid-ethanol soluble non-suppressible in insulin-like activity (NSILA-S).

Franklin RC, Rennie GC, Burger HG, Cameron DP.

Clin Endocrinol (Oxf). 1980 Feb;12(2):127-36.

PMID:
6772355
48.

The occurrence of a distinct high molecular weight form of serum non-suppressible insulin-like activity.

Franklin RC, Cameron DP, Burger HG, Herington AC.

Mol Cell Endocrinol. 1979 Nov;16(2):81-9.

PMID:
41788
50.

Acid-ethanol-extractable nonsuppressible insulin-like activity (NSILA-S) during pregnancy and the puererium, and in cord serum at term.

Franklin RC, Pepperell RJ, Rennie GC, Cameron DP.

J Clin Endocrinol Metab. 1979 Apr;48(4):695-9.

PMID:
429513

Supplemental Content

Loading ...
Support Center